Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial-Reference-Cited by-同舟云学术

Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial

Published:2020-01 Issue:1 Volume:2 Page:e14-e23
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Colmegna Inés,Useche Mariana L,Rodriguez Katherine,McCormack Deirdre,Alfonso Giuliana,Patel Aakash,Ramanakumar Agnihotram V,Rahme Elham,Bernatsky Sasha,Hudson Marie,Ward Brian J

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference34 articles.

1. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study;Iuliano;Lancet,2018

2. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis;Mertz;BMJ,2013

3. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host;Rubin;Clin Infect Dis,2014

4. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study;Blumentals;BMC Musculoskelet Disord,2012

5. Seasonal influenza vaccine in immunocompromised persons;Bosaeed;Hum Vaccin Immunother,2018

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert Panel Consensus Statements on Vaccination for Adults with AIRD in India;Indian Journal of Rheumatology;2024-09-04

2. Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE;Infectious Diseases and Therapy;2024-05-27

3. Consenso para la gestión de riesgo en la prescripción de terapias biológicas o de antirreumáticos sintéticos con blanco dirigido: Asociación Colombiana de Reumatología 2023;Revista Colombiana de Reumatología;2024-04

4. Vaccination updates and special considerations for systemic lupus erythematosus patients;Current Opinion in Rheumatology;2023-11-16

5. COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series;RMD Open;2023-11